The human genome contains essentially the same DNA sequence in almost every somatic cell, yet different cell types exhibit remarkably different patterns of gene expression and biological functions. This diversity is achieved partly through epigenetic regulation, which controls the accessibility and activity of genomic regions without requiring changes in the DNA sequence.

Epigenetic regulation involves several interconnected mechanisms, including DNA methylation, histone modifications, chromatin remodeling, nucleosome positioning, and non-coding RNA-mediated regulation. These mechanisms determine whether particular genes are transcriptionally active or repressed and are essential for cellular differentiation, development, metabolism, immune responses, and tissue homeostasis. (Springer)

Epigenetic patterns are dynamic and can respond to environmental and physiological conditions. Factors such as nutrition, aging, physical activity, smoking, environmental pollutants, metabolic disturbances, and chronic stress can influence the epigenome. Persistent alterations may disrupt normal gene-expression patterns and contribute to disease development. Recent evidence particularly emphasizes the role of epigenetic changes as an interface between environmental exposures and chronic disease susceptibility. (PubMed Central (PMC))

Chronic human diseases generally develop through complex interactions between genetic predisposition, environmental exposure, lifestyle, and cellular responses. Epigenetic mechanisms provide a biological framework capable of integrating these factors. Aberrant epigenetic regulation has been reported in metabolic disorders, cardiovascular disease, kidney disease, neurological disorders, autoimmune conditions, and cancer. (ScienceDirect)

Unlike permanent changes in the DNA sequence, many epigenetic modifications are potentially reversible. This characteristic has generated considerable interest in developing epigenetic biomarkers and therapeutic approaches. DNA methyltransferases, histone-modifying enzymes, chromatin regulators, and non-coding RNAs are being investigated as potential targets for disease intervention.

The objective of this review is to describe the major mechanisms of epigenetic regulation and examine their contribution to the pathogenesis and progression of chronic human diseases, with particular emphasis on molecular mechanisms, biomarkers, and therapeutic opportunities.

2. Major Mechanisms of Epigenetic Regulation

2.1 DNA Methylation

DNA methylation is one of the most extensively studied epigenetic mechanisms in humans. It generally involves the addition of a methyl group to the fifth carbon of cytosine, particularly at cytosine-phosphate-guanine (CpG) sites.

DNA methylation is regulated primarily by DNA methyltransferases. DNMT1 is important for maintenance of existing methylation patterns during DNA replication, whereas DNMT3A and DNMT3B contribute to de novo methylation.

Promoter-associated DNA methylation frequently correlates with transcriptional repression because methylation can interfere with transcription-factor binding and promote recruitment of proteins involved in chromatin compaction.

However, the biological effects of methylation depend on genomic location and cellular context. Methylation within gene bodies and regulatory regions can have different consequences for gene expression.

Abnormal DNA methylation patterns have been reported in cancer, autoimmune disease, metabolic disorders, cardiovascular disease, and other chronic conditions. (ScienceDirect)

3. Histone Modifications

Histones are proteins around which DNA is organized to form chromatin. Their amino-terminal tails contain residues that can undergo various post-translational modifications.

Important histone modifications include:

• Acetylation
• Methylation
• Phosphorylation
• Ubiquitination
• Sumoylation

Histone acetylation is commonly associated with a more open chromatin structure and increased transcriptional accessibility. Histone deacetylases remove acetyl groups and can promote chromatin condensation and transcriptional repression.

Histone methylation has more complex effects. Depending on the specific histone residue and degree of methylation, it may promote either transcriptional activation or repression.

For example, H3K4 methylation is generally associated with active transcription, whereas H3K9 and H3K27 methylation are frequently associated with transcriptionally repressed chromatin.

Abnormal histone modification can alter cellular differentiation, inflammatory signaling, metabolic pathways, and tumor-suppressor activity.

4. Chromatin Remodeling

Chromatin remodeling involves ATP-dependent molecular complexes that alter nucleosome positioning and chromatin accessibility.

Remodeling complexes can expose DNA sequences to transcription factors or alternatively make genomic regions less accessible.

Major chromatin-remodeling families include SWI/SNF, ISWI, CHD, and INO80 complexes.

Alterations in chromatin-remodeling proteins have been associated particularly with cancer, developmental disorders, and chronic inflammatory conditions.

Because chromatin remodeling determines which genomic regions are accessible for transcription, abnormalities can produce widespread changes in cellular gene expression.

5. Non-Coding RNAs

Non-coding RNAs are RNA molecules that do not primarily function as templates for protein synthesis. They represent an important additional layer of epigenetic and post-transcriptional regulation.

Major classes include:

• MicroRNAs
• Long non-coding RNAs
• Circular RNAs
• Small interfering RNAs

MicroRNAs generally regulate gene expression by binding complementary sequences within target messenger RNAs and promoting degradation or inhibiting translation.

Long non-coding RNAs can interact with DNA, RNA, chromatin-modifying proteins, and transcription factors. Some lncRNAs act as molecular scaffolds that recruit epigenetic enzymes to specific genomic regions.

Non-coding RNAs have been implicated in metabolic disorders, cardiovascular disease, neurodegeneration, cancer, and inflammatory diseases.

6. Epigenetic Regulation and Chronic Inflammation

Chronic inflammation is a common feature of many long-term diseases.

Epigenetic mechanisms regulate the expression of inflammatory mediators, immune receptors, transcription factors, and signaling proteins.

DNA methylation can alter the expression of inflammatory genes, while histone modifications can influence accessibility of promoters and enhancers involved in inflammatory responses.

NF-κB, STAT signaling, and other inflammatory pathways interact extensively with epigenetic regulators.

Persistent inflammatory stimuli may consequently establish stable epigenetic patterns that maintain abnormal gene expression even after the original stimulus has declined.

This interaction between inflammation and epigenetic regulation may contribute to the persistence of chronic disease.

7. Epigenetic Regulation in Cardiovascular Diseases

Cardiovascular disease is influenced by genetic, metabolic, environmental, and behavioral factors.

Epigenetic alterations have been identified in endothelial cells, vascular smooth muscle cells, cardiomyocytes, immune cells, and circulating blood cells.

Abnormal DNA methylation can influence genes involved in lipid metabolism, vascular integrity, inflammation, oxidative stress, and blood-pressure regulation.

Histone modifications may regulate vascular inflammatory responses and cardiac remodeling.

MicroRNAs also participate in endothelial function, angiogenesis, myocardial hypertrophy, fibrosis, and vascular inflammation.

Recent research has emphasized the relationship between metabolic status and epigenetic regulation in cardiovascular disease, suggesting that epigenetic changes may represent both biomarkers and potential therapeutic targets. (Nature)

8. Epigenetic Mechanisms in Diabetes Mellitus

Type 2 diabetes mellitus is characterized by insulin resistance, impaired insulin secretion, chronic inflammation, and metabolic dysfunction.

Epigenetic mechanisms can influence genes involved in glucose transport, insulin signaling, pancreatic β-cell function, lipid metabolism, and inflammatory pathways.

Changes in DNA methylation have been reported in pancreatic islets, adipose tissue, skeletal muscle, liver, and circulating blood cells.

Histone modifications can influence transcriptional programs associated with glucose metabolism and inflammatory signaling.

MicroRNAs also regulate insulin signaling and pancreatic β-cell function. Several microRNAs have been investigated as potential biomarkers for diabetes and its complications.

Importantly, metabolic abnormalities can themselves influence epigenetic pathways, creating a feedback relationship between metabolism and gene regulation. (PubMed)

9. Epigenetic Regulation in Obesity

Obesity is associated with chronic low-grade inflammation, altered lipid metabolism, insulin resistance, and endocrine dysfunction.

Epigenetic changes can influence adipocyte differentiation, appetite regulation, energy expenditure, lipid storage, and inflammatory signaling.

Nutritional factors can alter the availability of metabolic substrates required for epigenetic reactions. For example, cellular concentrations of acetyl-CoA, S-adenosylmethionine, and other metabolites can influence histone acetylation and DNA methylation.

This metabolic-epigenetic interaction provides a potential explanation for how long-term dietary patterns can influence gene-expression programs.

Epigenetic alterations in adipose tissue may consequently contribute to persistent metabolic dysfunction.

10. Epigenetic Mechanisms in Chronic Kidney Disease

The kidney is particularly sensitive to metabolic, inflammatory, and oxidative stress.

Epigenetic mechanisms influence renal fibrosis, inflammation, oxidative stress, vascular dysfunction, and cellular injury.

DNA methylation abnormalities can affect genes associated with extracellular matrix production and renal inflammation.

Histone modifications may regulate pathways involved in fibrosis and inflammatory signaling.

Non-coding RNAs have also been implicated in the progression of chronic kidney disease and diabetic kidney disease.

Recent research has emphasized that epigenetic changes may contribute to the persistence of disease-associated molecular programs, sometimes referred to as epigenetic memory. (Springer)

11. Epigenetics and Neurodegenerative Diseases

Neurons require highly regulated gene expression to maintain synaptic function, plasticity, metabolism, and survival.

Epigenetic alterations have been implicated in Alzheimer's disease, Parkinson's disease, Huntington's disease, and other neurodegenerative disorders.

DNA methylation changes can influence genes involved in neuronal survival and inflammation.

Histone acetylation affects transcription of genes required for learning, memory, and synaptic plasticity.

Non-coding RNAs can regulate neuronal signaling, protein aggregation, oxidative stress, and neuroinflammation.

Age-associated changes in the epigenome may further increase susceptibility to neurodegenerative disease.

12. Epigenetics and Cancer

Cancer represents one of the best-established examples of disease associated with abnormal epigenetic regulation.

Tumor cells may demonstrate global DNA hypomethylation combined with localized hypermethylation of tumor-suppressor gene promoters.

These alterations can lead to inappropriate activation of oncogenes and silencing of genes involved in DNA repair, apoptosis, and cell-cycle control.

Mutations in epigenetic regulators can also alter histone modification and chromatin organization.

Epigenetic abnormalities can therefore contribute to tumor initiation, progression, metastasis, drug resistance, and interaction between tumor cells and the immune system.

Because epigenetic alterations are potentially reversible, epigenetic therapy has become an important area of cancer research.

13. Epigenetics and Autoimmune Diseases

The immune system depends on tightly controlled gene expression.

Epigenetic abnormalities can alter immune-cell differentiation and inflammatory signaling, potentially contributing to autoimmune disease.

Changes in DNA methylation and histone modification have been reported in conditions such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

Epigenetic changes may influence the activity of T cells, B cells, macrophages, and other immune populations.

The interaction between genetic susceptibility and epigenetic regulation may therefore help explain why environmental factors can influence the onset and severity of autoimmune diseases.

14. Environmental Factors and Epigenetic Changes

The epigenome is sensitive to environmental influences throughout life.

Important factors include:

• Tobacco smoke
• Air pollution
• Dietary patterns
• Alcohol exposure
• Physical inactivity
• Psychological stress
• Environmental chemicals
• Heavy metals
• Obesity
• Chronic inflammation

These exposures can influence DNA methylation, histone modifications, chromatin structure, and non-coding RNA expression.

Environmental epigenetics therefore provides a mechanistic framework through which external exposures can influence long-term disease susceptibility.

Recent research emphasizes that age and tissue or cell type are among the strongest determinants of epigenetic patterns, complicating attempts to distinguish disease-related changes from normal biological variation. (OUP Academic)

15. Epigenetic Biomarkers in Chronic Disease

One of the most promising applications of epigenetic research is biomarker development.

Epigenetic biomarkers may potentially be used for:

1. Early disease detection;
2. Risk prediction;
3. Disease classification;
4. Prognostic assessment;
5. Monitoring treatment response;
6. Identifying high-risk individuals.

DNA methylation is particularly attractive because methylation patterns can be measured in biological samples such as blood.

Epigenome-wide association studies have identified disease-associated methylation patterns across multiple chronic diseases.

However, biomarker development requires careful validation because methylation patterns can differ according to age, sex, ethnicity, cell composition, tissue type, medication, and environmental exposure.

Review Design

This article was prepared as a narrative review addressing the molecular mechanisms of epigenetic regulation and their relationship with chronic human diseases.

Literature Search

Scientific literature was evaluated using biomedical databases and peer-reviewed journals.

Search terms included combinations of:

“epigenetics,” “gene expression,” “DNA methylation,” “histone modification,” “chromatin remodeling,” “non-coding RNA,” “microRNA,” “long non-coding RNA,” “chronic disease,” “diabetes,” “obesity,” “cardiovascular disease,” “cancer,” “chronic kidney disease,” “neurodegeneration,” “autoimmune disease,” “epigenetic biomarkers,” and “epigenetic therapy.”

Recent studies were emphasized, while foundational studies were included to explain established molecular mechanisms.

Inclusion Criteria

Studies were considered relevant when they:

• Examined epigenetic regulation of gene expression;
• Investigated chronic human diseases;
• Described DNA methylation or histone modifications;
• Examined chromatin remodeling or non-coding RNAs;
• Evaluated epigenetic biomarkers; or
• Investigated epigenetic therapeutic strategies.

Exclusion Criteria

Publications with limited relevance to human epigenetic regulation or chronic disease mechanisms were excluded from the principal synthesis.

Data Synthesis

Evidence was organized according to major epigenetic mechanisms and disease categories. Findings were synthesized to identify common molecular pathways, disease-specific alterations, diagnostic opportunities, and therapeutic implications.

17. Results

The reviewed evidence demonstrates that epigenetic regulation is a central component of gene-expression control in chronic human disease.

Several major observations were identified.

First, DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs interact to regulate gene expression.

Second, chronic diseases are frequently associated with disease-specific alterations in epigenetic patterns.

Third, metabolic and environmental factors can influence the epigenome, providing a potential molecular link between lifestyle, environmental exposure, genetic susceptibility, and disease.

Fourth, epigenetic changes are involved in inflammation, oxidative stress, metabolic dysfunction, fibrosis, immune regulation, and abnormal cellular proliferation.

Fifth, epigenetic alterations have potential applications as diagnostic and prognostic biomarkers.

Finally, the reversibility of many epigenetic modifications provides opportunities for therapeutic intervention.

Recent comprehensive evidence supports the involvement of epigenetic mechanisms across cardiovascular, metabolic, neurological, autoimmune, and other chronic disorders. (PubMed)

18. Therapeutic Perspectives

DNA Methyltransferase Inhibitors

DNA methyltransferase inhibitors can reduce abnormal DNA methylation and potentially restore expression of silenced genes.

These compounds have already demonstrated clinical utility in selected hematological malignancies.

However, nonspecific modulation of DNA methylation may affect both beneficial and harmful gene-expression programs, emphasizing the need for more selective approaches.

Histone Deacetylase Inhibitors

Histone deacetylase inhibitors increase histone acetylation and can alter chromatin accessibility.

Several compounds targeting histone deacetylases have been investigated clinically, particularly in oncology.

Their potential applications in inflammatory, neurological, metabolic, and cardiovascular diseases are also being explored.

RNA-Based Therapeutics

Because non-coding RNAs participate extensively in gene regulation, therapeutic manipulation of microRNAs and other RNA molecules represents an emerging strategy.

Potential approaches include:

• MicroRNA mimics
• Antisense oligonucleotides
• MicroRNA inhibitors
• Small interfering RNAs
• Long non-coding RNA modulation

These approaches could provide greater specificity than broad epigenetic enzyme inhibition.

Lifestyle-Based Epigenetic Modulation

Lifestyle interventions may influence epigenetic patterns.

Regular physical activity, balanced nutrition, adequate sleep, weight management, and avoidance of tobacco exposure can influence metabolic and inflammatory pathways that interact with the epigenome.

Although lifestyle interventions should not be considered replacements for medical treatment, understanding their epigenetic effects may contribute to preventive medicine.

Precision Epigenetic Therapy

Future therapies may focus on specific disease-associated epigenetic abnormalities rather than globally modifying the epigenome.

Advances in sequencing, single-cell technologies, CRISPR-based epigenome editing, and computational biology may enable precise modification of selected genomic regulatory regions.

Epigenetic regulation provides an important molecular connection between genetic information and environmental conditions.

Unlike DNA mutations, epigenetic modifications can potentially be altered during an individual's lifetime. This characteristic makes them particularly relevant to chronic diseases, which frequently develop through long-term interactions between inherited susceptibility and environmental exposure.

DNA methylation represents one of the most extensively studied mechanisms. Aberrant methylation can silence protective genes or alter the expression of genes involved in metabolism, inflammation, immune regulation, and cellular proliferation. Evidence from human disease studies demonstrates the potential value of DNA methylation as both a mechanistic factor and a biomarker. (ScienceDirect)

Histone modifications add another layer of complexity. Because histone acetylation, methylation, phosphorylation, and ubiquitination can alter chromatin structure, abnormal regulation of histone-modifying enzymes may produce persistent changes in transcription.

Non-coding RNAs further expand the regulatory network. A single microRNA can potentially influence multiple target genes, while long non-coding RNAs can interact with chromatin and transcriptional machinery.

An important feature of chronic disease is the interaction between metabolism and epigenetics. Cellular metabolites can act as substrates or cofactors for enzymes that modify DNA and histones. Consequently, metabolic disturbances may directly influence gene regulation at the epigenetic level. (PubMed)

Environmental exposures represent another important component. Smoking, pollution, nutrition, stress, and other exposures may alter epigenetic states. However, interpreting these changes remains challenging because epigenetic patterns are strongly influenced by age and tissue or cell type. (OUP Academic)

A major challenge is determining whether an epigenetic alteration is a cause or consequence of disease. Many studies identify associations but cannot establish causality. Longitudinal studies, experimental models, and advanced statistical approaches are therefore needed.

Another challenge is tissue specificity. An epigenetic signature detected in blood may not accurately represent molecular changes occurring in a diseased organ.

Nevertheless, the field is progressing rapidly. The development of epigenome-wide association studies, single-cell sequencing, spatial technologies, and computational approaches is improving the ability to characterize disease-associated epigenetic patterns.

The therapeutic potential of epigenetic regulation is particularly promising because many modifications are reversible. Current research is moving toward more selective strategies capable of correcting disease-associated regulatory changes while minimizing effects on normal gene expression.

20. Future Perspectives

Future research should focus on establishing causal relationships between epigenetic changes and chronic disease.

Large longitudinal studies will be necessary to determine whether specific epigenetic signatures can predict disease before clinical symptoms develop.

Single-cell and spatial epigenomic technologies may allow researchers to identify disease-associated changes in specific cell populations rather than relying solely on whole-tissue measurements.

The development of highly specific epigenome-editing technologies could further improve therapeutic precision.

Another important area will be integration of epigenetic data with genomic, transcriptomic, proteomic, metabolomic, and clinical information.

Such integrated approaches may support the development of personalized medicine in which disease prevention and treatment are guided by an individual's genetic and epigenetic profile.

Epigenetic regulation is a fundamental mechanism controlling gene expression and cellular function. DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs work together to establish and maintain cellular transcriptional programs.

Aberrant epigenetic regulation has been associated with numerous chronic human diseases, including cardiovascular disease, diabetes, obesity, chronic kidney disease, neurodegenerative disorders, autoimmune diseases, and cancer.

Environmental and metabolic factors can modify epigenetic states, providing an important molecular link between lifestyle, environmental exposure, genetic susceptibility, and disease development.

Epigenetic alterations may serve as biomarkers for disease detection, risk assessment, prognosis, and treatment monitoring. Their potential reversibility also makes them attractive therapeutic targets.

However, important challenges remain, particularly regarding causality, tissue specificity, temporal variation, individual variability, and potential off-target effects of epigenetic therapies.

Continued advances in molecular biology, epigenomics, computational science, and precision medicine are expected to improve understanding of disease-associated epigenetic mechanisms and facilitate the development of targeted interventions for chronic human diseases.

1. Bird A. Perceptions of epigenetics. Nature. 2007;447:396–398.
2. Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nature Reviews Genetics. 2016;17:487–500.
3. Cedar H, Bergman Y. Programming of DNA methylation patterns. Annual Review of Biochemistry. 2012;81:97–117.
4. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature Reviews Genetics. 2012;13:484–492.
5. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705.
6. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Research. 2011;21:381–395.
7. Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. New England Journal of Medicine. 2018;378:1323–1334.
8. Portela A, Esteller M. Epigenetic modifications and human disease. Nature Biotechnology. 2010;28:1057–1068.
9. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–463.
10. Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational implications. Nature Reviews Cancer. 2011;11:726–734.
11. Esteller M. Epigenetics in cancer. New England Journal of Medicine. 2008;358:1148–1159.
12. Feinberg AP. Epigenetics at the epicenter of modern medicine. JAMA. 2008;299:1345–1350.
13. Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metabolism. 2019;29:1028–1044.
14. Zaina S, Heyn H, Carmona FJ, et al. DNA methylation map of human atherosclerosis. Circulation. 2014;129:2459–2470.
15. Bell CG. Epigenomic insights into common human disease pathology. Cellular and Molecular Life Sciences. 2024;81:178.
16. Jirtle RL. Epigenetics, human imprintome, and chronic diseases. Essays in Biochemistry. 2025;69:229–247.
17. Sasaki K, Masaki T. Epigenetic histone modifications in kidney disease and epigenetic memory. Clinical and Experimental Nephrology. 2025;29:1129–1138.
18. Webster AK, Phillips PC. Epigenetics and individuality: from concepts to causality across timescales. Nature Reviews Genetics. 2025;26:406–423.
19. Swathi NL, Shakhatreh Z, Tahir A, et al. Epigenetic mechanisms in the transfer of metabolic disorders: a comprehensive review. Cureus. 2025;17:e80418.
20. Kaimala S, Yassin LK, Hamad MIK, et al. Epigenetic crossroads in metabolic and cardiovascular health: the role of DNA methylation in type 2 diabetes and cardiovascular diseases. Cardiovascular Diabetology. 2025;24:231.
21. Ouyang J, Wu D, Gan Y, et al. Unraveling the metabolic-epigenetic nexus: a new frontier in cardiovascular disease treatment. Cell Death & Disease. 2025.
22. Hoyo C, Martin CL, Murphy SK. Environmental exposures and epigenetic alterations in common chronic diseases: insights and challenges. Environmental Epigenetics. 2026;12:dvag014.
23. Jones PA, Issa JPJ, Baylin S. Targeting the cancer epigenome for therapy. Nature Reviews Genetics. 2016;17:630–641.
24. Gibney ER, Nolan CM. Epigenetics and gene expression. Heredity. 2010;105:4–13.
25. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011;123:2145–2156.